Wedbush Thinks ObsEva SA’s Stock is Going to Recover
Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA (OBSV) yesterday and set a price target of $28.00. The company’s shares closed last Tuesday at $2.09, close to its 52-week low of $1.63.
According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 17.6% and a 59.0% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ObsEva SA with a $22.50 average price target, representing a 976.6% upside. In a report issued on January 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $17.00 price target.
See today’s analyst top recommended stocks >>
Based on ObsEva SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $24.38 million. In comparison, last year the company had a GAAP net loss of $27.61 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.